Geode Capital Management LLC Grows Stake in Coya Therapeutics, Inc. (NASDAQ:COYA)

Geode Capital Management LLC raised its holdings in Coya Therapeutics, Inc. (NASDAQ:COYA) by 3.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 142,309 shares of the company’s stock after acquiring an additional 4,485 shares during the quarter. Geode Capital Management LLC’s holdings in Coya Therapeutics were worth $918,000 at the end of the most recent reporting period.

Separately, GHP Investment Advisors Inc. purchased a new stake in Coya Therapeutics in the third quarter valued at approximately $169,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on COYA shares. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday, December 18th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Stock Down 4.9 %

Shares of NASDAQ COYA opened at $5.77 on Friday. The company has a market cap of $96.40 million, a price-to-earnings ratio of -8.88 and a beta of 0.46. The firm’s fifty day moving average is $6.16 and its 200 day moving average is $6.50. Coya Therapeutics, Inc. has a 52 week low of $4.75 and a 52 week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. Equities research analysts anticipate that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Insider Activity at Coya Therapeutics

In related news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The shares were acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the transaction, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired a total of 9,510 shares of company stock worth $69,615 in the last 90 days. Company insiders own 12.00% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.